Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Eye Care

Journal Scan / Research · July 13, 2019

Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of DME With Aflibercept, Bevacizumab, or Ranibizumab

JAMA Ophthalmology

 

Additional Info

Disclosure statements are available on the authors' profiles:

JAMA Ophthalmology
Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab: A Post Hoc Analysis of the Protocol T Randomized Clinical Trial
JAMA Ophthalmol 2019 Jun 27;[EPub Ahead of Print], NM Bressler, I Odia, M Maguire, AR Glassman, LM Jampol, MW MacCumber, C Shah, D Rosberger, JK Sun

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading